| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2019: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2018: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2016: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
In many human cancer cells, epigenomic aberrations result in up-regulation of oncogenes. The BET protein binds to highly-acetylated histone H4 and is involved in carcinogenesis. Inhibitors for BET proteins can bring the gene expression pattern in cancer cell back to that of normal cells. However, the effect of the BET inhibitor on the hyperacetylation of histone H4, which is the primary target of BET protein binding to the epigenome, has been unclear. In this study, we observed that treatment of a human lung cancer cell line with a BET inhibitor JQ1 could not change the K5/K8-diacetylated status of histone H4 at all, suggesting that the combinatorial modification of H4K5acK8ac is a robust marker of the cancer epigenome.
|
